The companies say that a phase 3 trial of 1,795 early-stage Alzheimer’s patients shows that giving lecanemab reduces the rate of cognitive decline by 27% compared to those given a placebo. The drug is a monoclonal antibody that attacks the amyloid plaques of the neurons of the patients, one of the main hypotheses for the origin of the disease, which has not yet been proven. In the trial, it was administered twice a week for a period of 18 months.
“Encouraging results increase the chances of approval of the therapy early next year”spread the Washington Postregarding the medication Lecanemab reduced abnormal accumulations of beta amyloid, a hallmark of Alzheimer’s disease. This result, as stated, “increases the chances of approval of this therapy early next year.”
The drug “met the primary and secondary endpoints of the 18-month late-stage study” although it was clarified that “the trial results have not been peer-reviewed.”
The results of the experiment
The trial included nearly 1,800 patients with mild cognitive impairment caused by Alzheimer’s disease or early-stage Alzheimer’s disease.
As assessed, “a 27% decrease in impairment appears to be a modest effect, but for Alzheimer’s patients, this could be highly significant.”
However, we cautioned that the drug’s benefits are “likely” to be “small” and therefore we wanted to see the full data before reaching any conclusions.
Source: Ambito
David William is a talented author who has made a name for himself in the world of writing. He is a professional author who writes on a wide range of topics, from general interest to opinion news. David is currently working as a writer at 24 hours worlds where he brings his unique perspective and in-depth research to his articles, making them both informative and engaging.
